Supplements and Featured Publications
Novel Approaches to Targeting TSC1/TSC2 Across Malignancies
Volume 1
Issue 1

Dr. Iyer on Unmet Needs for Patients With TSC1/2-mutated Solid Tumors


Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.

Gopa Iyer, MD, section head, Bladder Cancer, Memorial Sloan Kettering Cancer Center, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.

Although standard-of-care treatments exist for patients with TSC1/2 mutations across different cancer types, these patients may ultimately experience disease progression over time, Iyer explains. Developing a targeted therapy for solid tumors harboring TSC1/2 mutations remains an intriguing avenue for research, Iyer adds.

TSC1/2 mutations are relatively rare among individual tumor types; however, the collective population across different solid tumors represents a meaningful number of patients. A tumor-agnostic targeted therapy would stand to benefit these patients, Iyer adds.

The safety and efficacy of nab-sirolimus (ABI-009) monotherapy is under evaluation in the phase 2 PRECISION 1 trial (NCT05103358), a basket study that is currently enrolling patients with malignant solid tumors harboring pathogenic inactivating TSC1 or TSC2 alterations.

Related Videos
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD
Anthony M. Hunter, MD
Amrita Krishnan, MD, City of Hope
Jonathan C. Trent, MD, PhD